Lidak Pharm. [LDAKA] Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA]

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: henry jakala who wrote (731)	12/23/1997 10:55:00 AM
From: John Zwiener	Read Replies (1) of 1115

To all (3 of you), I do have some reservation as to how the press releases were worded. In a second press release, they are even less clear that the 8-10 days refers to the placebo group... LIDAK said it submitted its application to the Food and Drug Administration four months after Phase III clinical trials showed the drug reduced healing time and symptoms in treated patients. <<<<It said patients treated with Lidakol were healed in an average of 4.1 days, compared with eight to 10 days in most untreated cases.>>>>> Notice that they say "compare with eight to 10 days in MOST untreated cases"...... In the other press release, they don't specifically say placebo, but say NORMAL duration. I'm sorry, but at this time I feel they continue to be vague. As scientists, they know the correct buzzwords to specify what they mean. They must compare Lidakol treated versus the placebo control group (not the normal duration). Lidak continues to be evasive,

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next